ROSSELLA ELISEI

Associate Professor of Endocrinology

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rossella Elisei is an Associate Professor of Endocrinology at Rossella Elisei, Italy. Her research focuses on the genetics and treatment of thyroid cancer, particularly in relation to MEN2 syndromes and medullary thyroid carcinoma. Recent publications explore areas such as the prevalence of genetic mutations, treatment-related syndromes, and the effectiveness of radioiodine therapy in differentiated thyroid cancer.

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (7)

Fulvio Basolo

University of Pisa

ITALY

View details

Maria Cristina Campopiano

University of Pisa

ITALY

View details

Anello Poma

University of Pisa

ITALY

View details

COSIMO DURANTE

Associate Professor of Internal Medicine/MD, PhD

Sapienza University of Rome

ITALY

View details

Alessandro Prete

University of Pisa

ITALY

View details

Carla Gambale

University of Pisa

ITALY

View details

Francesco Latrofa

University of Pisa

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ROSSELLA ELISEI

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Prevalence and genetics of “de novo” MEN2 syndromes

Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature

Hand–foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer

A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib

Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib

Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance

Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors

Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features

Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination

Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test

Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma

BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review

Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit

Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib

Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma

Collaborators (7)

Fulvio Basolo

Maria Cristina Campopiano

Anello Poma

COSIMO DURANTE

Alessandro Prete

Carla Gambale

Francesco Latrofa

Make your next move.